SciClone Takes Deeper Plunge In China Following Solid Q1 Results
This article was originally published in PharmAsia News
SciClone sees more opportunities ahead as it plans deeper expansion into China, following Q1 results that posted a 38% increase in sales for its lead product.
You may also be interested in...
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.